Market Overview

UPDATE: Bank of America Merrill Lynch Reiterates Buy Rating, Raises PT on Eli Lilly & Co.

Share:
Related LLY
Eli Lilly Shares Go Parabolic
Sales Of This Eli Lilly Drug Could Nearly Double Wall St. Consensus In 2020, SunTrust Predicts
Eli Lilly and Immunocore team up in melanoma; early stage trials to start in 2016 (Seeking Alpha)

In a report published Wednesday, Bank of America Merrill Lynch reiterated its Buy rating on Eli Lilly & Co. (NYSE: LLY), and raised its price target from $57.00 to $60.00.

BofA Merrill Lynch noted, “LLY offers a good mix of compelling valuation, an attractive dividend yield with a track record of returning cash to shareholders, and pipeline optionality. Several promising late-stage pipeline assets are underappreciated, in our view, and could be transformative to LLYs growth trajectory (ramucirumab, solanezumab and the four Phase III diabetes assets - two basal insulins, empagliflozin and dulaglutide).”

Eli Lilly & Co. closed on Tuesday at $51.88.

Latest Ratings for LLY

DateFirmActionFromTo
Jun 2015Leerink SwannMaintainsOutperform
Jun 2015Bank of AmericaUpgradesNeutralBuy
Jun 2015Argus ResearchMaintainsBuy

View More Analyst Ratings for LLY
View the Latest Analyst Ratings

Posted-In: Bank of America Merrill LynchAnalyst Color Price Target Analyst Ratings

 

Related Articles (LLY)

Around the Web, We're Loving...

Get Benzinga's Newsletters